Peter Hillmen P, Badoux X, Delgado J, et al. Safety results of terminated phase 2 study of idelalisib plus rituximab in treatment naïve chronic lymphocytic leukemia (CLL) with del(17p). EHA 2017, abstract S465.
Behandeling met emicizumab bij ernstige hemofilie alleen in basispakket na prijsdaling
feb 2020 | Benigne hematologie